Nanoparticle crossing of blood-brain barrier: A road to new therapeutic approaches to central nervous system diseases
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
the increase in lifespan in Western countries predicts that CNS diseases
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As such, the appropriate size range for DDS is between 100 and 200 nm.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [24]
In the citing paper
“however, to be able to cross the BBB, the literature indicates that NPs should be smaller than 200 nm [24].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [24]
Citations
Cites
Cost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
Lindgren, M., Hällbrink, M., Prochiantz, A., & Langel, Ü. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01447-4 · Cited by 803
Lin, T., Zhao, P., Jiang, Y., Tang, Y., Jin, H., Pan, Z., He, H., Yang, V. C., & Huang, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b04268 · Cited by 527
Wiley, D. T., Webster, P., Gale, A., & Davis, M. E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307152110 · Cited by 519
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
The burden of neurological disease in theUnitedStates: A summary report and call to action
Gooch, C. L., Pracht, E., & Borenstein, A. R. (2017) · Annals of Neurology · doi:10.1002/ana.24897 · Cited by 388
Designing super selectivity in multivalent nano-particle binding
Martinez-Veracoechea, F. J., & Frenkel, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105351108 · Cited by 346
Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting
Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306
Cited by
Items 201–232 of 232
Kowalska, A., Adamska, E., Zima, K., Nowicka, P., Wcisło, A., Makowski, M., & Grobelna, B. (2025) · Dalton Transactions · doi:10.1039/d5dt02168e · Cited by 2
Bonato, M., Galletta, V., Zhang, E., Cancino-Fuentes, N., Chiaramello, E., Fiocchi, S., Sanchez-Vives, M. V., & Parazzini, M. (2025) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc58623.2025.11254136 · Cited by 1
“These nanoparticles offer several advantages: they can cross the blood-brain barrier, have demonstrated good biocompatibility, and convert non-invasive, remote, low-power (10-150 mT) and low-frequency (1-1000 Hz) magnetic fields into localized electric fields [10][11].”
Lee, J.-W., Jen, C.-T., Inbaraj, B. S., & Chen, B. (2026) · Antioxidants · doi:10.3390/antiox15020195 · Cited by 2
“Thus, to remedy the problem associated with crossing the BBB by hydrophilic or lipophilic compounds, the development of a nanosystem such as nanoliposome or nanoemulsion with an optimal size is pivotal [3,23,78].”
Yu, L., Rana, M. N., Quan, C., Zhou, Z., Chen, Z., Gao, X., & Gao, X. (2026) · Toxicology Letters · doi:10.1016/j.toxlet.2026.111873 · Cited by 2
Kaya, M. Z., Gültekin, Y., Çelebier, M., Soyseven, M., Vural, İ., Öner, L., Ayata, C., Pehlivan, S. B., & Harriott, A. M. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126743 · Cited by 1
Séguy, L., Guyon, L., Corvaisier, S., Maurel, M., Verdié, P., Herbinet, R., Pluart, L. L., Dehouck, L., Sevin, E., Fénart, L., et al. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127181 · Cited by 1
Nanotoxicity in neural regenerative medicine
Çakır-Koç, R., Çalık, H., Mutlu, B., Ay, H. F., Karavelioğlu, Z., Aslan-Polat, B., & Pençeci, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820223-4.00008-5 · Cited by 1
Role of nanomedicine for targeted drug delivery in life-threatening diseases
Tuteja, J., & Sand, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98387-7.00004-5 · Cited by 1
Rise of Nanotechnology for Neurological Disorders Management
Saxena, H., Kumar, A., Solanki, P., & Bhandari, K. G. (2023) · Springer eBooks · doi:10.1007/978-981-99-9510-3_2 · Cited by 2
Liposomes as a Potential Carrier for Brain Delivery
Thakur, A. S., Vishwas, S., Badwaik, H., Paul, S. D., Sakure, K., & Nakhate, K. T. (2024) · Springer eBooks · doi:10.1007/978-981-97-2859-6_6 · Cited by 2
Lu, C. T., Tang, H., Ouyang, J., & Zhang, J. (2024) · Journal of Applied Polymer Science · doi:10.1002/app.56278 · Cited by 3
Nanocrystals: a new herald for the management of Alzheimer’s disease
Patel, V. F., Rajput, M. S., Patel, A. K., Patel, M., & Patel, R. J. (2024) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2024.2409443 · Cited by 1
“[19,21] BBB also assists in the metabolism of numerous chemicals and the excretion of waste, at the same time it also shields the brain from alteration of cerebrospinal fluid’s ionic composition.”
Development Of A Liposomal Formulation For Brain Targeting
Zhang, Z. (2020) · Cited by 1
Drug-loaded nanoclusters for brain targeting
Pathan, N., & Shende, P. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90773-6.00003-8
Hippocampal organotypic cultures as ex vivo model for tissue response to upconverting nanoparticlesPreprint
Zajdel, K., Janowska, J., Frontczak‐Baniewicz, M., Sypecka, J., & Sikora, B. (2022) · Research Square · doi:10.21203/rs.3.rs-2067842/v1
Utility of nanomedicine and nanocarriers for noninfectious disease treatment
Tuteja, J., Vyas, A., & Sand, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95325-2.00014-6 · Cited by 2
Unraveling the Intricacies of Nanoparticle Targeting of Brain Therapeutics for Enhanced EfficacyPreprint
Yousfan, A., Rahwanji, M. J. A., Hanano, A., & Al-Obaidi, H. (2023) · Research Square · doi:10.21203/rs.3.rs-3016363/v1
Role of inflammation, angiogenesis and oxidative stress in developing epilepsy
Wal, P., Vig, H., Alnasser, S. M., Khan, M. M. U., Mishra, A. K., & Behl, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13587-3.00014-x · Cited by 1
Lama, A. D., Fernández‐Bertólez, N., Colás, L., No-Gomez, M., Ramos‐Cabrer, P., Valdiglesias, V., Sarandeses, L. A., & Martínez, M. M. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108107
Sandhu, J. K., Thakur, K., Cai, D., Péladeau, C. L., Hewitt, M., & Ghadban, W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22300-6.00055-3 · Cited by 1
Quantum dots as an advanced nanosystem for cancer theranostics
Bakhshi, A., & Naghib, S. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24064-5.00005-6
Nanotechnology-based approaches for vitiligo
Tiwari, P. K., Kadiri, S. K., & Husain, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36326-9.00001-0
Abioye, A. O. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00005-3
Advancements in Brain Tumor Treatment: Harnessing Nanotechnology for Promising Solutions
Patel, D. J., Patel, V., & Patel, U. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898811747125010007
Toxicological concerns in the commercialization of nanoscale thin films for biomedical applications
Vysakh, V. G., Sukumaran, S., Ashok, A., & Gopalakrishnan, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-18929-6.00021-9
Hamdaoui, Q. (2021) · theses.fr (ABES) · doi:10.70675/80460aadz3953z465dz98edz35fe1486c591 · Cited by 2
He, Z., Meng, Z., luan, G., Li, P., Yang, C., Liang, Y., Sun, X., Zhao, L., Wang, G., & Wang, X. (2026) · Biomaterials Research · doi:10.34133/bmr.0365 · Cited by 1
Sandhu, J. K., Tanha, J., & Arbabi‐Ghahroudi, M. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671675 · Cited by 2
“They enter cells via endocytosis, RMT, macropinocytosis, or phagocytosis [122], and must escape the endosomal pathway to avoid lysosomal degradation [123] (Figure 4(B)).”
Yazdani, S., Pazuki, G., Mozaffarian, M., & Hadidi, N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33639-3.00006-4
Barkat, M. A., Rahman, S., Barkat, H. A., Alanezi, A. A., Namazi, N. I., Almuqati, A. F., Turki, A., Alali, Z., Sharma, M. K., & Raza, K. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070897
Abdel-Rasol, M. A. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02386-0 · Cited by 1
“BBB-targeted delivery efficiency is influenced by nano - carrier physicochemical properties, including size, shape, surface charge, ligand density, colloidal stability, and pro-tein-corona composition (Ceña and Játiva 2018).”
Nanomedicines with triiodothyronine and their effects on neurological tissues
Dixit, T., Chattopadhyay, S., Thakur, T., Sawardekar, M., & Ravindran, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30261-9.00018-8
Metadata
- Authors
- Ceña, V., & Játiva, P.
- Affiliations
- Unidad Asociada Neurodeath, Universidad de Castilla-La Mancha, Albacete, Spain
- Instituto de Salud Carlos III (ES)
- ORCID
- Játiva, Pablo
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-07
- Volume
- 13
- Issue
- 13
- Pages
- 1513-1516
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2868168748
- Semantic Scholar
- f5267cc2f2cb4aee9679939ee9c77f593ddb94ac
- Cited by
- 232
- References
- 21
- Citations by year
- 2026: 14 · 2025: 27 · 2024: 31 · 2023: 47 · 2022: 45 · 2021: 32 · 2020: 21 · 2019: 14 · 2018: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nanomedicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- blood-brain barrier, nanoparticles, nanoparticle delivery, central nervous system disorders, brain drug delivery, neurodegenerative diseases, neuroinflammation
- MeSH terms
- Biological Transport, Blood-Brain Barrier, Central Nervous System, Central Nervous System Diseases, Humans, Drug Delivery Systems, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.